Cases
Idera Pharmaceuticals, Inc. (IDRA)
Merger
Overview
Overview
- Date:
- 1/22/2018
- Company Name:
- Idera Pharmaceuticals, Inc.
- Stock Symbol:
- IDRA
- Company Name - Buyer:
- BioCryst Pharmaceuticals, Inc.
- Stock Symbol - Buyer:
- BCRX
- Status:
- Closed/Complete
NEW YORK, January 22, 2018 – Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) stockholders concerning the proposed merger of the company with BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX).
Our investigation concerns whether Idera’s board of directors failed to adequately shop the company and obtain the best possible value for its stockholders before entering into a definitive merger agreement with BioCryst. Under the terms of the agreement, Idera stockholders will receive 0.20 shares of the combined company stock for each share of Idera common stock they own. On a proforma, fully diluted basis, Idera stockholders will own 48.4 percent of the combined company.
If you own Idera shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
Our investigation concerns whether Idera’s board of directors failed to adequately shop the company and obtain the best possible value for its stockholders before entering into a definitive merger agreement with BioCryst. Under the terms of the agreement, Idera stockholders will receive 0.20 shares of the combined company stock for each share of Idera common stock they own. On a proforma, fully diluted basis, Idera stockholders will own 48.4 percent of the combined company.
If you own Idera shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.